Table 1 The expression of CCR9 in cancer patients
From: CCR9 in cancer: oncogenic role and therapeutic targeting
Tumors | Cell type | Methods | Expression | References |
|---|---|---|---|---|
T-ALL | PBMCs (n = 21) | FCM | 91.9 % | [25] |
Melanoma | Circulating tumor cells (n = 21) | FCM | 57 % | [58] |
Melanoma | Primary specimens (n = 32) | IHC | 69.7 % | [59] |
Melanoma metastasis | Small intestinal metastases (n = 102) | QPCR | 86 % | [30] |
Mediastinal large B cell lymphomas | Lymphoid tissue (n = 22) | IHC | 90.9 %a | [60] |
Large B cell lymphoma | Gastric extranodal diffuse lymphoma (n = 10) | IHC | 58.33 % | [61] |
Large B cell lymphoma | Gastrointestinal lymphoma (n = 41) | IHC | 66 %b | [62] |
Ovarian cancer | Cancer tissues (n = 43) | IHC | Significantly higher | [11] |
Lung cancer | Lung biopsies (n = 50) | WB | 1.2c | [63] |
Hepatocellular carcinoma | Cancer tissues (n = 240) | IHC | 55.8 % | [9] |
Breast cancer | Moderately differentiated cancer tissues (n = 18) | IHC | 50 % | [64] |
Poorly differentiated cancer tissues (n = 18) | IHC | >75 % | ||
Colon cancer | Adenomatous foci (n = 46) | IHC | 2.26 ± 0.06d | [65] |
Nasopharyngeal carcinoma | Carcinoma tissues (n = 42) | IHC | 80.95 % | [66] |